CD86 and neoplasm: In addition, butyrate also inhibited CD80/CD86 expression on DCs, which impeded T cell priming and activation.114 The discrepancy in the conflicting results may be due to differences in experimental settings, such as anti-tumor therapy approaches, mouse tumor models, or SCFA doses/types used in each study.